Telix Pharmaceuticals plans to accelerate development of its radiopharmaceutical to treat the most aggressive form of brain cancer after encouraging … Read More
The post Initial trial results bolster evidence for Telix’s brain cancer treatment appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.